Bluejay Diagnostics, Inc.

BJDX

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001704287

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 6, 2026 254 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$2.80 2026-11-11; market equity $3.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 6, 2026

is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform ("Symphony"), which consists of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration (the "FDA") before Symphony can be marketed as a diagnostic product in the United States. We have completed the pre-clinical development of the Symphony analyzer.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 37.2						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(11.5%)	(6.6%)	37.2	799	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 54.1						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(16.09)	(0.31)	70.9	743	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	4.88x	2.96x	37.4	825	2025-12-31	
Growth and financing, sleeve percentile 85.7						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(19.3%)	2.3%	83.4	693	2025-12-31	
Net share issuance, one year	160.3%	2.4%	88.0	627	2026-03-02	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 160.3%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(89.2%)	(1.5%)	3
Distance from 52-week high	(57.9%)	(32.0%)	23
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	(213.6%)	(1.0%)	4
Book value to price	2.55	0.29	95
Sales to price	0.09	0.29	23
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(2.39)	(0.18)	3

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$7.4M
Operating cash flow, four quarters	-$6.5M
Months of runway	13.5
Days since last periodic filing	3 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$121,293

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$48,911	2022-12-31	2024-03-28	10-K	24-027305
2	assets	us-gaap:Assets	$13.5M	2022-12-31	2024-03-28	10-K	24-027305
3	net income	us-gaap:NetIncomeLoss	-$6.8M	2025-12-31	2026-03-06	10-K	26-024616
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.1M	2025-12-31	2026-03-06	10-K	26-024616
5	assets	us-gaap:Assets	$7.1M	2025-12-31	2026-03-06	10-K	26-024616
6	assets	us-gaap:Assets	$6.7M	2024-12-31	2026-03-06	10-K	26-024616
7	current assets	us-gaap:AssetsCurrent	$5.5M	2025-12-31	2026-03-06	10-K	26-024616
8	current liabilities	us-gaap:LiabilitiesCurrent	$1.1M	2025-12-31	2026-03-06	10-K	26-024616
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$41.5M	2025-12-31	2026-03-06	10-K	26-024616
10	operating income	us-gaap:OperatingIncomeLoss	-$7.0M	2025-12-31	2026-03-06	10-K	26-024616
11	book equity	us-gaap:StockholdersEquity	$6.0M	2025-12-31	2026-03-06	10-K	26-024616
12	liabilities	us-gaap:Liabilities	$1.1M	2025-12-31	2026-03-06	10-K	26-024616
13	revenue	us-gaap:Revenues	$249,040	2022-12-31	2024-03-28	10-K	24-027305
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$173,735	2025-12-31	2026-03-06	10-K	26-024616
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.8M	2024-12-31	2026-03-06	10-K	26-024616
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$306,783	2024-12-31	2026-03-06	10-K	26-024616
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.3M	2023-12-31	2025-03-31	10-K	25-026275
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$704,166	2023-12-31	2025-03-31	10-K	25-026275
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.7M	2022-12-31	2024-03-28	10-K	24-027305
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2M	2022-12-31	2024-03-28	10-K	24-027305
21	assets	us-gaap:Assets	$4.9M	2023-12-31	2025-03-31	10-K	25-026275
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	972,215	2026-03-02	2026-03-06	10-K	26-024616
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,494,167	2025-04-28	2025-04-29	10-K/A	25-036783

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.